Semaglutide could provide novel dual benefit in diabetes and kidney disease
European Pharmaceutical Review
MARCH 8, 2024
“Approximately 40 percent of people with type 2 diabetes have chronic kidney disease, so the positive results from FLOW demonstrate the potential for semaglutide to become the first GLP-1 treatment option for people living with type 2 diabetes and chronic kidney disease.”
Let's personalize your content